Sunlight May Help Protect Men From Kidney Cancer
By Dr. Matthew Watson
(HealthDay News) -- Men with jobs that expose them to high levels of sunlight are less likely to develop kidney cancer than those with little or no sunlight exposure at work, says a new study.
Previous research suggests that vitamin D, which is obtained from sun exposure and certain foods and supplements, may help prevent some cancers. Vitamin D is metabolized and most active within the kidneys.
This new study included 1,097 male and female kidney cancer patients and 1,476 healthy people in Europe who were interviewed about their work history and other demographic information.
Men with the highest levels of work-related exposure to sunlight were 24 percent to 38 percent less likely to have kidney cancer than other men. This association between job-related sunlight exposure and kidney cancer risk was not seen in women.
The study is published online March 8 in the journal Cancer. Read more...
ProShares Launches Two New Exchange Traded Funds Based on the NASDAQ … – CNNMoney.com (press release)
By Dr. Matthew Watson
ETF Database | ProShares Launches Two New Exchange Traded Funds Based on the NASDAQ ... CNNMoney.com (press release) 2 ProShares Ultra Nasdaq Biotechnology (Nasdaq:BIB) aims to provide investment results that correspond to 200% of the daily performance of the NASDAQ ... ProShares Launches First Leveraged and Inverse Biotechnology ETFsMarketWatch (press release) Avoid New Biotech Leveraged ETFsTheStreet.com (subscription) Double Your Biotech Returns! Really!Motley Fool Benzinga -Before It's News -Emii.com all 52 news articles » |
Generex Biotechnology Firms About 4% on Funding Commitment – ONN.tv
By Dr. Matthew Watson
BNET | Generex Biotechnology Firms About 4% on Funding Commitment ONN.tv by MidnightTrader.com April 8, 2010 11:07 EDT Related Symbols: GNBT 11:07 AM Eastern Daylight Time, 04/08/2010 (MidnightTrader) — Generex Biotechnology ... Generex Receives Funding CommitmentMarketWatch (press release) Generex Receives Funding CommitmentTrading Markets (press release) |
Trading looks for biotechs to decline – optionMONSTER Research (registration)
By Dr. Matthew Watson
ETF Trends (blog) | Trading looks for biotechs to decline optionMONSTER Research (registration) Unusual option action is showing that someone is positioning for a pullback in the Nasdaq Biotechnology Index Fund. The IBB exchange-traded fund is off 0.17 ... ETFs and EarningsTheStreet.com (subscription) Nine ETFs To Buy NowForbes This Week in ETFs: April 9th EditionETF Database |
US Sen. Bob Casey presents Hanover Township biotechnology company ABEC with award – The Express Times – LehighValleyLive.com
By Dr. Matthew Watson
The Express Times - LehighValleyLive.com | US Sen. Bob Casey presents Hanover Township biotechnology company ABEC with award The Express Times - LehighValleyLive.com Local biotechnology company ABEC received a prestigious national award Friday for its success breaking into the international marketplace. US Sen. ... Bob Casey presents award to Lehigh Valley businessThe Express Times - LehighValleyLive.com Sen. Bob Casey to visit ABEC Inc. company in Hanover TownshipThe Express Times - LehighValleyLive.com |
HIV invades through leaky cells: study – CBC.ca
By Dr. Matthew Watson
India Talkies | HIV invades through leaky cells: study CBC.ca The research was conducted in collaboration with researchers in the department of molecular genetics at the University of Toronto and the department of ... New way HIV infects women discoveredOneindia |
International Stem Cell Corporation Provides Strategic Update on its Skin Care Program
By Dr. Matthew Watson
OCEANSIDE, California - April 8, 2010 - International Stem Cell Corporation (ISCO.OB), http://www.internationalstemcell.com, announces today that it’s wholly owned subsidiary, Lifeline Skin Care Inc., has achieved positive results in human safety tests of its cosmetic products and is moving forward with arrangements with Cosmetic Enterprises Ltd. for the manufacture of three cosmetic products. These developments allow Lifeline Skin Care to plan a launch of its cosmetic product line in the late summer or fall of 2010.
Cosmetic face products developed by Lifeline Skin Care Inc., contain extracts from human parthenogenetic stem cells (hpSC) combined with a vitamin complex and other active ingredients. The products utilize a form of nanotechnology to deliver concentrated active ingredients to damaged skin. Laboratory tests show that an active “complex” of stem cell extract has the ability to rejuvenate skin. Also, early human trials show that these cosmetic products moisturize skin and strongly indicate the ability to decrease the depth of wrinkles and provide factors that lead to anti-aging effects.
Lifeline Skin Care is working with Cosmetic Enterprises, Ltd., located in California, to formulate and package its unique skin care product. Cosmetic Enterprises is a well-known OTC drug licensed manufacturer with over 30 years of experience. Lifeline Skin Care’s “parthenogenetic stem cell complex” the product’s active ingredient, is made in Lifeline Skin Care’s laboratory in Oceanside, California.
According to Gregory S. Keller, MD, FACS, “These positive safety studies in human testing are important, especially considering that preliminary human trial data show that products of the production of International Stem Cell’s parthenogenetic stem cells have significant beneficial effects on the skin and might also provide long term benefits in reducing wrinkles and other visible signs of aging. These results are a significant step forward in making this unique product available to the public.” Dr. Keller was named the 2007 “Specialist of the Year in Facial Cosmetic Surgery” in Strathmore’s “Who’s Who”.
The results of recent human safety tests show there were no identifiable signs or symptoms of sensitization (contact allergy). Safety testing is a series of tests to insure the product does not cause negative reactions such as irritation to the skin. This completed round of testing allows Lifeline Skin Care to move forward confidently with its commercial manufacturing plans.
International Stem Cell Corporation is a pioneer in development of a new class of stem cells called “human parthenogenetic stem cells” which avoid critical ethical issues by eliminating the need to use fertilized embryos and can be immune-matched to large segments of the population. As of today, ISCO has successfully derived 10 hpSC lines. One of these lines (hpSC-Hhom-4), carries the most common immune type found across racial groups within the US population and can be immune-matched to millions of people.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO’s core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO’s website, http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Skin Care, Stem Cells, Biotechnology, Parthenogenesis
CONTACTS:
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Lifeline Skin Care Inc.
Ruslan Semechkin, PhD, CEO
760-940-6383
ras@intlstemcell.com
Generex Launches $250000000 Lawsuit Against TheStreet.com and Feuerstein – MarketWatch (press release)
By Dr. Matthew Watson
TheStreet.com | Generex Launches $250000000 Lawsuit Against TheStreet.com and Feuerstein MarketWatch (press release) WORCESTER, Mass., Apr 6, 2010 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (NASDAQ:GNBT) (www.generex.com), the leader in drug delivery ... Generex: What Happens in India, Stays in IndiaTheStreet.com TheStreet stands up to Generex's bullyingEthiopian Review Generex Launches $250000000 Lawsuit Against TheStreet.com and FeuersteinTrading Markets (press release) |
Faulty Circuits (preview)
By Dr. Matthew Watson
In most areas of medicine, doctors have historically tried to glean something about the underlying cause of a patient’s illness before figuring out a treatment that addresses the source of the problem. When it came to mental or behavioral disorders in the past, however, no physical cause was detectable so the problem was long assumed by doctors to be solely “mental,” and psychological therapies followed suit.
Today scientific approaches based on modern biology, neuroscience and genomics are replacing nearly a century of purely psychological theories, yielding new approaches to the treatment of mental illnesses.
Biocon buys out Cuban firm in JV, hopes to break even in 5 yrs – Business Standard
By Dr. Matthew Watson
Hindu Business Line | Biocon buys out Cuban firm in JV, hopes to break even in 5 yrs Business Standard Biocon Ltd, the Bangalore-based biotechnology company, is taking full ownership of its subsidiary, Biocon Biopharmaceuticals Pvt Ltd (BBPL) by buying the ... Biocon acquires 49% Cuban partner CIMAB's stake in JVEconomic Times Biocon acquires stake of CIMAB in joint ventureTimes of India Biocon gains after buying out JV partner in unitBloombergUTV Reuters -Financial Express all 28 news articles » |
Genetic Engineering Raises Hope for Lyme Disease Vaccine – U.S. News & World Report
By Dr. Matthew Watson
USA Today | Genetic Engineering Raises Hope for Lyme Disease Vaccine U.S. News & World Report MONDAY, April 5 (HealthDay News) -- In an effort to combat Lyme disease, researchers have found that tick-borne transmission might be ... One change in bacteria keeps ticks from passing along Lyme diseaseUSA Today |
Turmeric and Amla Health Remedies
By Dr. Matthew Watson
Be Your Own Doctor
There various vegetables , fruits and nuts readily available in our kitchens and our local markets. But we often forget the medicinal value and no soon we have a ailment we run to the doctors for help. It is very important to consult a doctor and take the medication, but the herbal medicenes that are available readily at our kitchen could help us if the ailment is very nominal. For eg. if someone has a gastric problem, or an acidity problem , then there are so many condiments, and other herbal cures which are at our reach, but that goes unnoticed or being ignored. I give you a few remedies on very normal and common ailments from the vegetables, condiments, fruits etc available at home.
1. Amla (indian gooseberry) Genera-Phylanthus Speices-emblica Read more...